Target intelligence / Profile preview

Zinc ion in synaptic neurotransmission (Zn²⁺)

Target: Zn²⁺
Molecular classification: Other (metalloneuromodulator), Not a receptor, channel, or enzyme itself; zinc acts via modulating:, Ion channel (especially NMDA and AMPA glutamate receptors), Transporter (glutamate transporters)

Overview

Zinc is contained in synaptic vesicles of certain glutamatergic neurons, co-released with glutamate during neurotransmission. Once released, zinc can modulate postsynaptic receptor activity, notably inhibiting NMDA receptor function at nanomolar concentrations, though its effects depend on receptor subunit composition, localization (synaptic vs extrasynaptic), and the rate of neuronal activity. Zinc also influences AMPA and GABA receptors, and alters glutamate uptake by transporters, exerting a biphasic physiological effect depending on its concentration. This modulation plays a protective role against excitotoxicity by limiting excessive NMDA receptor activity and may fine-tune synaptic transmission, but disruption of zinc balance is associated with neurological disorders including stroke, epilepsy, and neurodegeneration.

Other names: Zincergic modulationZinc neurotransmissionSynaptic zinc regulationZinc-glutamate co-release

Mechanism of action

Zinc acts as a non-competitive inhibitor of NMDA receptors (especially GluN2A-containing subtypes). Allosteric modulation of AMPA and GABA receptors (inhibition or potentiation depending on subunit composition). Regulation of glutamate uptake (by modulating glutamate transporters). Biphasic concentration-dependent facilitation or inhibition of glutamate release.

Biological functions

NeuromodulationSynaptic transmissionRegulation of excitatory neurotransmissionNeuroprotectionInhibition/facilitation of receptor activity (NMDA, AMPA, GABA)Homeostatic control of glutamate levels

Disease associations

Neurodegenerative disease (altered zinc-glutamate interaction implicated in excitotoxicity, neuroprotection, stroke)Epilepsy (presynaptic zinc regulation affects synaptic excitability)Psychiatric disorders (potential roles in cognitive impairment, depression via glutamatergic dysfunction)Other (role in ischemia, synaptic injury)

Safety considerations

Zinc homeostasis disruption can contribute to neurotoxicity (excitotoxicity, oxidative stress)Chelation or excess can impair physiological zinc function and glutamatergic balanceTherapeutic challenges include selective targeting without adverse effects on essential zinc functions and overall brain metal homeostasis

Interacting drugs

Zinc chelators (ZX1, tricine, CaEDTA, used experimentally)

2 more in the full profile.

Biomarkers

Extracellular zinc levels in synapses or brain regions (can be measured with fluorescent probes such as LZ9)ZnT3 transporter expression (marker of synaptic zinc storage)

Beyond the preview

Go deeper on Zinc ion in synaptic neurotransmission (Zn²⁺).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc ion in synaptic neurotransmission (Zn²⁺).

Explore the full profile